New Research 10: Car-T Therapy for Severe Autoimmune Disease

Chimeric antigen receptor (CAR) T-cell therapy has cleared another hurdle on the path to potentially becoming a viable treatment option for people with severe autoimmune diseases.

... Zorpocabtagene autoleucel (Zorpo-cel, formerly MB-CART19.1) from Germany-based Miltenyi Biomedicine and zolacabtagene autoleucel (Zola-cel, formerly BMS-986353) from Bristol Myers Squibb — are autologous CD19 agents tested in populations with systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies (IIM), relapsing multiple sclerosis, progressive multiple sclerosis, or myasthenia gravis.

.... “The major bridge through in this entire endeavor is that, for the very first time in severe autoimmune diseases, you actually have a treatment-free period,” Fabian Müller, MD, a senior attending physician and head of the CAR T-Cell Unit at University Hospital Erlangen in Erlangen, Germany. read details here... https://www.medscape.com/viewarticle/new-autoimmune-disease-car-t-results-tremendous-success-2026a10004ml?ecd=mkm_ret_260318_mscpmrk_derm_AutoimmuneSkinDisease_etid8197183&uac=234181DY&impID=8197183